SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Blueprint Medicines Reports Progress In Systemic Mastocytosis Treatment

reuters.com · 06/09/2022 07:10
BRIEF-Blueprint Medicines Reports Progress In Systemic Mastocytosis Treatment

- Blueprint Medicines Corp BPMC:

  • BLUEPRINT MEDICINES REPORTS CONTINUED PROGRESS TOWARD GOAL OF TRANSFORMING TREATMENT OF SYSTEMIC MASTOCYTOSIS

  • BLUEPRINT MEDICINES-NEW ANALYSES SHOWING AYVAKIT SIGNIFICANTLY IMPROVED OVERALL SURVIVAL IN ADVANCED SM VERSUS REAL-WORLD DATA FOR PRIOR STANDARD THERAPIES

  • BLUEPRINT MEDICINES - PRIMARY ENDPOINT OF PIONEER TRIAL OF AYVAKIT IN NON-ADVANCED SM TO BE UPDATED TO MEAN CHANGE IN TOTAL SYMPTOM SCORE

  • BLUEPRINT MEDICINES CORP - ON TRACK TO REPORT TOP-LINE REGISTRATIONAL DATA FROM PIONEER TRIAL IN LATE SUMMER 2022

  • BLUEPRINT MEDICINES -CONTINUES TO PLAN TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR AYVAKIT FOR NON-ADVANCED SM BY END OF 2022

Source text for Eikon: ID:nPnbfwGfma

Further company coverage: BPMC


((Reuters.Briefs@thomsonreuters.com;))